Stereotaxis announced that Robocath's next-generation robotic system achieved a 100% clinical success rate with no device-related adverse events in a pilot study of 20 first-in-human coronary interventions. Conducted by cardiologists in France, the study demonstrated the system's ability to handle complex coronary procedures efficiently while protecting physicians from radiation exposure. These promising results highlight the system's potential to improve patient care and physician safety, with plans underway for regulatory submissions and wider clinical use.
Robocath's next-generation robotic system clinical study results are the subject here. For readers following the health sector, of 150 priced US health stocks tradable on Pluang, 87 rose and 43 fell today. Notable movers include IDXX at USD 586.99 (+6.49%), FLNA at USD 0.66 (+6.11%), and ALMS at USD 7.04 (+4.45%). This data is as of Nov 02, 2026 20:02 WIB.
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
UroGen Pharma has dosed the first patient in a Phase 1 trial testing UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). The trial aims to evaluate the safety and tolerability of UGN-501 administered directly in...
